SAN FRANCISCO — In women with type 1 diabetes using closed-loop insulin delivery systems, menstrual cycle phase does not have an impact on trends toward increased time in range, according to study results presented at the American Diabetes Association 79th Scientific Sessions, held June 7 to 11, 2019, in San Francisco, California.
Given that many women with type 1 diabetes report changes in glucose control and insulin dosing throughout their menstrual cycle, researchers aimed to examine whether closed-loop control affects insulin delivery patterns over the menstrual phases. The investigators logged data from 64 menstrual cycles of 27 women age 28 ± 11 years, 13 who used closed-loop insulin delivery and 14 who used sensor-augmented pumps. Data were analyzed for daytime glucose control and closed-loop control insulin delivery.
Study results showed that menstrual cycle phase did not have an impact on trends toward increased time in range (70 to 180 mg/dL) with closed-loop insulin delivery and there were no differences found in glucose and insulin variables. Although median closed-loop insulin delivery did not change, there was variability among participants throughout the menstrual cycle phases.
“Closed-loop control has the potential to elucidate individual dosing variability and may mitigate reported change in glucose control across the menstrual cycle,” according to the researchers.
Disclosures: Multiple authors disclosed associations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.
Levy CJ, O’Malley G, Brown SA, et al. Glucose variability throughout the menstrual cycle on closed-loop control in type 1 DM. Presented at: American Diabetes Association 79th Scientific Sessions; June 7-11, 2019; San Francisco, CA. Poster 118-LB.